Terms: = Breast cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
491 results:
1. car-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
2. breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After car-T Therapy Detected by
Perrone E; Taralli S; Pagliara D; Larocca LM; Vinti L; Leccisotti L
Anticancer Res; 2024 May; 44(5):2243-2245. PubMed ID: 38677722
[TBL] [Abstract] [Full Text] [Related]
3. Factors affecting heterogeneity in breast cancer microenvironment: A narrative mini review.
Ganguly A; Mukherjee S; Chatterjee K; Spada S
Int Rev Cell Mol Biol; 2024; 385():211-226. PubMed ID: 38663960
[TBL] [Abstract] [Full Text] [Related]
4. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
5. B7-H3 Expression in breast cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract] [Full Text] [Related]
6. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive breast cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.
Kashyap D; Salman H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612592
[TBL] [Abstract] [Full Text] [Related]
7. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted car-NK cells against human esophageal squamous cell carcinoma.
Lin X; Guan T; Xu Y; Li Y; Lin Y; Chen S; Chen Y; Wei X; Li D; Cui Y; Lin Y; Sun P; Guo J; Li C; Gu J; Yang W; Zeng H; Ma C
Front Immunol; 2024; 15():1337489. PubMed ID: 38566988
[TBL] [Abstract] [Full Text] [Related]
9. Universal car T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Nagy L; Mezősi-Csaplár M; Rebenku I; Vereb G; Szöőr Á
Front Immunol; 2024; 15():1365172. PubMed ID: 38562932
[TBL] [Abstract] [Full Text] [Related]
10. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract] [Full Text] [Related]
11. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.
Zhu L; Man CW; Harrison RES; Wu Z; Limsakul P; Peng Q; Hashimoto M; Mamaril AP; Xu H; Liu L; Wang Y
ACS Nano; 2024 Mar; 18(11):8531-8545. PubMed ID: 38456901
[TBL] [Abstract] [Full Text] [Related]
12. car-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
[TBL] [Abstract] [Full Text] [Related]
13. Targeting the activated microenvironment with endosialin (CD248)-directed car-T cells ablates perivascular cells to impair tumor growth and metastasis.
Ash SL; Orha R; Mole H; Dinesh-Kumar M; Lee SP; Turrell FK; Isacke CM
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38413223
[TBL] [Abstract] [Full Text] [Related]
14. car-NK cells for cancer immunotherapy: recent advances and future directions.
Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of MUC1-targeted car-NK cells against human tongue squamous cell carcinoma.
Lin X; Guan T; Li Y; Lin Y; Huang G; Lin Y; Sun P; Li C; Gu J; Zeng H; Ma C
Front Immunol; 2024; 15():1337557. PubMed ID: 38390321
[TBL] [Abstract] [Full Text] [Related]
16. Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis.
Zhang Y; Song M; Yang Z; Huang X; Lin Y; Yang H
BMC Cancer; 2024 Feb; 24(1):208. PubMed ID: 38360584
[TBL] [Abstract] [Full Text] [Related]
17. Cytotoxicity of fourth-generation anti-Trop2 car-T cells against breast cancer.
Somboonpatarakun C; Phanthaphol N; Suwanchiwasiri K; Ramwarungkura B; Yuti P; Poungvarin N; Thuwajit P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2024 Mar; 129():111631. PubMed ID: 38359664
[TBL] [Abstract] [Full Text] [Related]
18. Influence of copper(I) nicotinate complex on the Notch1 signaling pathway in triple negative breast cancer cell lines.
Abdel-Mohsen MA; Badawy AM; Abu-Youssef MA; Yehia MA; Abou Shamaa LD; Mohamed SA
Sci Rep; 2024 Jan; 14(1):2522. PubMed ID: 38291201
[TBL] [Abstract] [Full Text] [Related]
19. New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
[TBL] [Abstract] [Full Text] [Related]
20. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
[Next]